Objective -To examine the clinical, genetic, and molecular characteristics of a group of MJD patients recently identified in the southernmost state of Brazil, and compare these data with studies from the literature. Methods -Some 62 individuals from 35 families, mostly of Azorean ancestry, had their clinical data and their MJD1 expanded regions examined. Results -The present patients had an earlier age of onset, on average, than Portuguese-Azorean cases. Their survival, proportion of types, average anticipation, proportion of affected versus non-affected siblings, neurological signs and molecular findings are similar to those observed in patients previously described. Type 1 patients with male transmission showed worse anticipations than type 1 patients with female transmission. Patients with type 1 had also larger CAG expansions than other patients. Conclusions -The Brazilian origin seemed to affect the age of onset. We also noted that there were no differences other than the neurological between types 2 or 3, since both are similar in age of onset, disease duration and length of CAG repeats. We addressed the question of maintaining or not subtypes 2 and 3 separated, among patients with genetic and geographical backgrounds like the presented patients here.
Machado-Joseph disease (MJD) is an autosomal dominant multisystem degeneration manifested as a form of spinocerebellar ataxia. MJD was first reported in North American families of Portuguese-Azorean ancestry (1) (2) (3) . Besides being the main SCA diagnosed among Portuguese descendants, MJD has also been reported in many other countries. In Portuguese patients the mean age of onset is 40.5 years and the mean survival is 15.6 years (4). In Brazilian patients the mean age of onset was reported as 34 years (5) .
Clinically, MJD is characterized by a progressive cerebellar ataxia with associated features, including progressive ophthalmoplegia, pyramidal signs, dystonic posturing, distal muscular atrophies, eyelid retraction, faciolingual fasciculations, and no mental involvement. The different clinical expressions of MJD resulted in its classification into 3 clinical types: type 1 shows an early onset and a rapid course, and patients have marked pyramidal and extrapyramidal signs besides ataxia and ophthalmoplegia; type 2, the most common subtype, starts in the fourth decade of life and is limited to cerebellar ataxia and ophthalmoplegia, with or without pyramidal signs, and peripheral and extrapyramidal signs being mild or absent; and type 3 shows the latest onset, with a clinical picture that adds peripheral signs to those found in type 2 (4, 6) .
The MJD1 locus was mapped to chromosome 14q (7) . The gene was identified and contains a CAG repeat in the 5k region of the coding sequence, which is expanded in MJD patients (8) . Normal alleles show between 12 and 40 CAG repeats, whereas mutant alleles show between 61 and 84 repeats (9) . The disease often shows unstable CAG transmission between generations, a significant onset anticipation, and a strong inverse correlation between length of repeat and age of onset. Among the clinical types, type 1 is associated with larger repeats (9, 10) .
The purpose of the present study was to examine the clinical, genetic, and molecular characteristics of a group of MJD patients recently identified in the southernmost state of Brazil, and compare these data with studies from the literature.
Subjects and methods

Subjects
Sixty-two MJD patients from 35 families were identified in a previous survey (11) . Patients included in the present study were submitted to clinical interview, neurological examination and molecular investigation. Fifty-four of them had a CAG expansion detected at MJD1 locus. Eight patients were not typed, but were included, provided that they had the usual clinical picture and that they belonged to a molecular diagnosed family.
To study some variables, like age of onset within different generations and the effect of gender of affected parent, we added information from 93 welldocumented affected relatives, to whom we did not have direct access, totalling 155 cases -76 men and 79 women.
Methods
All patients were interviewed and examined by the same physician (L.B.J.). A standardized procedure included age of onset determination, disease duration, first sign of onset and a thorough neurological examination. Onset was considered as being the time when the patient or a close relative was able to date the appearance of the first symptom.
The MJD1 polymorphic expanded regions were analysed according to conditions previously described (12) .
Statistical analyses of data on clinical histories, heredograms, neurologic examination and molecular results, were performed using SPSS for Windows.
Differences in ages at onset between sexes and between parent-and-sib, as well as sex proportions, disease duration and repeat number of CAGs in the MJD allele among the three clinical types, were assessed by analysis of variance or by chi-square test, according to the type of variables under study. When there were only two independent groups to be compared and the variable was quantitative, differences were assessed by t-test. When the distribution of the quantitative trait was unknown or was not normal, the non parametric MannWhitney U-test was used. Correlations between two quantitative traits, like ages at onset and number of CAG repeats, were assessed by Pearson's correlation test.
Results
General clinical findings
The identified MJD patients belonged to 31 families of Portuguese ancestry, to three Afro-Brazilian families, and to one family of German ancestry. Seven families had three to eight individuals tested, being the majority of families represented by one case only.
The average age of onset was calculated as 32.1 years (SD=11.9), and was similar among men (31.4) and women (32.8) (t-test NS), ranging from 8 to 56 years. Among the deceased cases with welldocumented data (10 men and 10 women), the mean survival was of 17 years (range=5 to 30 years; SD=7) and did not differ among sexes.
The 62 examined patients were classified based only on neurological criteria, irrespective of their ages at onset. Patients with severe pyramidal and extrapyramidal findings were classified as MJD type 1. Individuals with significant lower motor neuron findings -amyotrophy or fasciculations and/or sensitive loss on lower extremities -patients unable to discriminate between tactile and algesic stimulations, or with a vibration sense smaller than 11 s on their first toes, were classified as type 3. Patients with none of the above-mentioned findings in a severe form were classified as type 2. We then found 8 patients with MJD type 1 (13%), 26 with MJD type 2 (42%), and 21 with MJD type 3 (34%). We were unable to classify 7 cases (11%), because patients presented simultaneously with severe extrapyramidal and peripheral findings, and for this reason we referred to them as ''unclassified''.
Using these exclusive neurological criteria, we found a significant difference between the average ages at onset of type 1 patients and the other two subtypes (P<0.0001, ANOVA). The mean age of onset was 15.2 years old (SD=2.15 years) in type 1 patients, 33 years old (SD=11.3 years) in type 2 patients and 37 years old (SD=7.4 years) in type 3 patients. ''Unclassified'' patients showed a mean age of onset of 26.8 years (SD=10.5).
Since it has been stated that all patients are type 2 at the time of onset of MJD, and that only after 4 to 5 years the real type is finally established (4), we looked at differences in the duration of the disease among our patients. The mean duration of the disease in the total sample was of 9.8 years (SD=6), and did not differ between men and women. Among the types, type 1 subgroup has disease duration statistically shorter than type 3 (P<0.05, ANOVA) and ''unclassified'' cases (P<0.02) (Fig. 1) . The mean duration of types 2 and 3 did not differ significantly in any comparison, but especially when one is compared to another (Fig. 1 ).
When patients with disease duration shorter than 5 years were excluded, even then there were no differences between age of onset of type 2 and type 3 cases (34 and 35.6 years, respectively) and between disease duration (11 and 12.8 years, respectively).
Among patients classified as type 2, there were 4 cases with an early onset of disease -13, 19, 20 and 22 years of age. Their disease durations were of 6, 23, 15 and 4 years, respectively. At least in two cases with long disease duration, it seems unlikely that their phenotype would change to type 1 with time.
The effect of gender of affected parent on phenotype of the affected child was evaluated, comparing ages at onset and clinical types in their respective sons and daughters. The phenomenon of anticipation was also examined.
The mean ages at onset, according to sex of the proband and of the affected parent, are shown in Table 1 : no significant differences were found. The distribution of clinical types according to the gender of affected parent was also homogeneous, fathers and mothers with the same proportion of children with types 1, 2 and 3 (chi-square NS).
In order to study anticipation, we followed 60 pairs of affected parent-child with well-documented ages at onset. In the majority of cases, there were important anticipations. The mean difference between age of onset of parent and child was of 7.7 years (SD=8.3), in the total sample (Fig. 2) . The standard deviation was larger than the mean value, because there were some instances where the parent's disease started at a more precocious age than the child's disease.
We also looked for differences in anticipations, according to the gender of the affected parent and, simultaneously, to the type of the proband. Among patients with type 1 MJD, the anticipation was really worse if the affected parent was the father (16.2 years), than if the affected parent was the mother (2.6 years) (P<0.0001, MannWhitney U-test) ( Table 1) .
Most of the 35 MJD pedigrees showed large sibships and comprised 4 or 5 adult generations. The variable age of onset of MJD turns doubtful to characterize a symptom-free individual as a non-carrier of the mutation, based only on information collected during a medical interview. However, it would be interesting to appreciate the proportions of affected versus non-affected sibs over 50 years of age -after excluding the index cases. It was found that 84 sibs were affected and 40 were not affected; or, on the other hand, that 68% of sibs over 50 years of age were affected, a result that is statistically different from the mendelian segregation (P<0.0001, chisquare).
Neurological findings
Gait ataxia was the initial sign in all patients and unsteadiness could be reliably dated. The neurological signs found in the present series were shown in Table 2 . Some findings deserve further comments. In 58/62 patients (93.5%), limb ataxia was noticed, but it was much less severe than the gait ataxia. Dysarthria was noticed in 53/62 patients (85.5%): its nature was cerebellar, pyramidal or pseudobulbar, and in 3 cases it progressed to anarthria. Pyramidal findings were present in 46/62 patients (74%), the majority of them being limited to hyperreflexia and Babinski sign, spasticity appearing in only 11 of 46 pyramidal cases (24%). Fasciculations were found in 25/61 patients (41%), occurring more frequently in periocular and peribuccal regions during intentional movements, and less, in resting limbs. Although fasciculations were common, amyotrophy, the other sign of lower motor neuron disease, was surprisingly infrequent in this sample: only 2 patients showed it. The contrary was strikingly present: well delineated muscles with preserved strength and power were seen in 15 patients (24%).
Molecular findings
The range of CAG repeat lengths found in the present sample was similar to those already described in literature: normal chromosomes varied between 14 and 38 CAG repeats, whereas MJD1 chromosomes varied between 69 and 85 repeats. Trinucleotide repeat lengths were highly correlated with disease age of onset: their correlation coefficient was of x0.68 (P<0.001, Pearson's correlation test). When repeat length of patients of different clinical types were compared, a significant difference was seen between type 1 and the other two classical types, with the expected tendency for increase severity with larger repeat sizes (P<0.0001, ANOVA) (Fig. 3) . No difference was found between CAG repeat lengths of type 2 and type 3 patients, even when patients with disease duration shorter than 5 years were excluded.
Patients who have not been typed showed all the four phenotypes: type 1 (one case), 2 (three cases), 3 (one case) and unclassified (three cases). The lack of their CAG data probably did not affect the present results.
Discussion
Ages of onset and ethnic background
In the present study, the mean age of onset of MJD patients was 32.1 years, similar to those found by another study in Brazilian patients (5) . Therefore, it is reasonable to say that onset in Brazilian patients is usually earlier than in Portuguese and Azorean patients (4) ( Table 3) , but is later than in Indian, Japanese and Black American patients (4). The resulting ages of onset for the three types were also 7 to 10 years earlier than those found in the Portuguese and Azorean descents (Table 3) . Genetic background influences the age of onset in MJD. One of the best known is the difference among Azorean people of Flores island and São Miguel (4). MJD patients originating from Flores have an onset on average 8 years earlier than those originating from Sã o Miguel. Unfortunately, the specific Azorean origin can not be proved in the present series. Besides this, a Flores origin is very unlikely, here the main Azorean settlements in South America dated from 1750 to 1755. In those years, around 7000 Azorean people emigrated to South Brazil, 2000 of them to our region, where they doubled the local population (14) . Historical documents pointed out that around 4% of the settlers originated from Sã o Miguel island, and none from Flores (14) .
Portuguese, Azorean and Spanish ancestries are the main components of our population, followed by African, German and Italian ones. This raises the possibility that the earlier age of onset among MJD Brazilian patients would be the result of our racial miscegenation. Or, maybe, it is reflecting the existence of some environmental influences. Either environmental or genetic, these factors are different, nowadays in Brazilian patients than those presented to their 8-10 generation ancestors from Azores. The identification of these factors might contribute to the future management of this condition.
Clinical subtypes
The differentiation of a unique, specific molecular disease into clinical subtypes deserves some reflection. If there are actual differences in independent variables among the three clinical subtypes, then one can say that the subtypes are not arbitrary but, on the contrary, their study helps us to look for factors that influence the natural history of the disease.
This was the reason why the age of onset was not used to classify patients in the present sample. Clinical definition of types 1-3 usually includes both neurological picture and age of onset (4) . In the present study, this criteria should be changed, in order to treat ''age of onset'' as an outcome variable: in other words, in order to see what were the actual ages of onset of the three subtypes. The differences in age of onset were then statistically significant between type 1 and other types, but were not different between type 2 and 3. Although it has already been found by others (10), this similarity (or absence of statistical difference) between types 2 and 3 was usually overlooked or interpreted as the result of a small sample.
The second variable analysed among the three subtypes was disease duration. Statistical differences were found only between type 1 and type 3 and ''unclassified'' cases, the former being shorter than the latter ones. The problem does not reside here, since type 1 patients seem to be unmistakable. What seems to be important are the similar means of disease duration of types 2 and 3: both were comparable and quite long. After several years of disease, some patients remained only with the main neurological findings of type 2, while others developed peripheral signs of type 3. If patients with disease duration shorter than 5 years were excluded, the same results were found.
The last variable analysed among the clinical types was the CAG repeat length of the expanded allele. In general, the molecular findings of the present series agreed with those already described in literature -the range of normal and of expanded alleles, the correlation between the trinucleotide repeat length in the MJD allele and age of onset of the disease and the relationship between type 1 and the larger repeat expansions (5, 9, 10) . It is known that the instability of the expanded CAG repeat provides only a partial explanation to the disease's great variability of clinical presentation: for example, in the present series, there were patients with type 1 whose CAG repeat had the same length of several found among types 2 and 3 ( Fig. 3) , 47% of the variability in age of onset being explained by the length of the expanded allele. With respect to Types 2 and 3, their CAG repeat lengths of expanded alleles were, again, comparable. So it seems that, in the present series, the outcome known as type 1 could have been determined by longer CAG repeat lengths or by earlier age of onset, or both. On the other hand, the two outcomes known as type 2 and 3 are clearly not associated with age at onset, nor with disease duration, and nor with the CAG repeat length. It is reasonable to question if there is really a distinction among type 2 and 3 MJD in the patients presented here, and if it can be generalized to others of genetic and geographical backgrounds similar to ours.
The effect of transmitting genitor
The effect of gender of affected parent over the phenotype was evaluated in several ways. No statistical associations were found between sex of affected parent and age of onset, proportion of clinical types and anticipation. The same can be said when the combination of sexes of parent-child pairs was examined. There were only suggestions, or tendencies, a) to relate an early age of onset and b) bad anticipation to sons of affected fathers, and c) to relate bad anticipations to type 1 patients rather to the other two types.
At first, it seems that the sex of the affected genitor do not influence the determination of clinical subtypes of his/her children, since there were as much types 1, 2 and 3 in female transmissions as there were in the male transmissions. If parental sex and clinical types were independent, their independent effects on anticipation could be added. It was found that, among type 1 patients, the anticipation in male transmission (16.2 years -5 cases) was worse than in female transmission (2.6 years -5 cases). Of course, these numbers showed that the affected mothers had early onset of their diseases, suggesting that, probably, they were also of type 1, but we can not be sure of this, because these women were not examined. It has been suggested that, among juvenile onset of MJD, an excess of female transmission could happen (9) . It didn't happen here, since the present type 1 patients with male transmission had ages at onset as early and juvenile as those with female transmission. In the present sample, it seems that a patient could have a type 1 evolution if his/her mother was already an early onset case, while male transmission somehow accelerated the appearance of this outcome in a given family.
Affirming that the proportion of affected versus non-affected sibs over 50 years of age was of 84:40 is risky, since some of the present non-affected could become symptomatic with time. Keeping in mind that it is an underestimation, even so it reaches a quite higher proportion than expected in an autosomal dominant disorder -68% . This finding is not surprising in MJD, a disorder in which evidences of preferential transmission of expanded over normal alleles have been already reported (13, 15, 16) .
In summary, it was found that MJD patients originated in the southernmost state of Brazil have an earlier age of onset, on average, than Portuguese and Azorean cases, and that this finding could not be explained by their origin among the diverse Azorean Islands. Their survival, the proportion of types, the average anticipation, the proportion of affected versus non-affected siblings, neurological signs in general and molecular findings are similar to patients already described in Portugal, Japan and United States. The disease duration of the present cases were quite long, which permitted a probably correct classification into the three types. Type 1 MJD patients with male transmission showed quite bad anticipations, in the present series. Patients with type 1 had the larger CAG expansions, as expected. Finally, the present paper stresses that no differences were found between types 2 or 3, since both types were similar in age of onset, disease duration and CAG repeat length.
